What ISPE Europe Revealed About the Future of Pharmaceutical Manufacturing

Michael Norman is a Market Adviser for Life Sciences and Healthcare at Enterprise Ireland Nordics.

At this year’s ISPE Europe Annual Conference in Copenhagen, the discussions focused a lot around how pharmaceutical manufacturing is shifting. Growth will always remain important, but the focus right now is increasingly on digitalisation, efficiency and sustainability, while maintaining high standards for quality and compliance.

These priorities are particularly relevant in the Nordics, a region that continues to play an outsized role in Europe's life sciences landscape. From Denmark's globally significant biopharmaceutical manufacturing base, led by Novo Nordisk, FujiFilm and others, to Sweden's strengths in biologics and advanced therapies, the Nordic region is often an early adopter of new technologies and manufacturing approaches.

One of the strongest themes throughout the conference was the shift from digitalisation as a strategic ambition to digitalisation as an operational necessity. Conversations are increasingly centred on practical applications of artificial intelligence, advanced analytics, digital twins and predictive maintenance. Manufacturers are no longer asking whether these technologies have a role to play. Instead, they are focusing on how to implement them effectively within highly regulated production environments.

This trend is particularly evident across the Nordic region. Pharmaceutical manufacturers are under pressure to improve productivity, reduce downtime and strengthen supply chain resilience while managing increasingly complex product portfolios. As a result, investments are increasingly focused on technologies that can improve decision-making, enhance process control and support operational excellence.

Another recurring discussion point was talent. Across Europe, manufacturers are competing for engineers, automation specialists, validation professionals and digital talent. The Nordics are no exception. While the region benefits from a highly skilled workforce, demand continues to grow as manufacturers invest in new facilities, biologics production and advanced manufacturing capabilities. Sustainability also featured prominently throughout discussions in Copenhagen. 

Environmental performance is becoming a core business consideration rather than a standalone compliance exercise. Nordic manufacturers have long been leaders in this area, and sustainability expectations are increasingly influencing investment decisions, supplier selection and facility design. Companies that can help reduce energy consumption, improve resource efficiency or support sustainability reporting are likely to find growing opportunities within the sector.

What stood out most, however, was the changing relationship between manufacturers and their suppliers. Pharmaceutical companies are increasingly looking beyond individual products and services. Instead, they are seeking partners who can support broader transformation programmes, whether in digitalisation, automation, sustainability or operational improvement. Technical expertise remains important, but the ability to collaborate and deliver long-term value is becoming equally critical.

For Enterprise Ireland clients, this presents a significant opportunity. Ireland has built a world class reputation in pharmaceutical manufacturing, engineering, process technologies, automation, validation and life sciences services. These capabilities align closely with the priorities currently shaping investment decisions across the Nordic region.

Success in the Nordics, however, is rarely built through transactional sales alone. Manufacturers place considerable emphasis on trust, technical credibility and long-term relationships. Companies that engage early, demonstrate expertise and invest time in understanding local market dynamics are often best positioned to succeed.

For Irish companies looking to build their presence in the region, participation in industry networks such as ISPE remains an important starting point. Equally valuable is developing relationships with Nordic manufacturers, engineering consultancies, CDMOs, system integrators and innovation clusters. Many of the strongest partnerships begin through technical collaboration, pilot projects and knowledge-sharing initiatives before evolving into larger commercial opportunities.

The key takeaway from Copenhagen was clear, the future of pharmaceutical manufacturing will be shaped not only by new technologies, but by the partnerships that enable their successful implementation. For Irish companies with relevant expertise, the Nordic region offers more than a market opportunity. It offers the chance to become a trusted partner in helping manufacturers navigate the next phase of industry transformation.

Our ambition is to see more Irish companies become trusted partners within the Nordic pharmaceutical manufacturing ecosystem, identifying an opportunity is only the beginning. Enterprise Ireland collaborated with industry experts prior to ISPE, held a well-attended industry webinar and contracted a pathfinder for 1:1 sessions to prepare companies travelling over. We aim to increase our activities in the Nordics hoping to attract more companies to explore the opportunities here.